CDK4/6 inhibitors in HER2-positive breast cancer

Abstract Notwithstanding the continuous progress made in cancer treatment in the last 20 years, and the availability of new targeted therapies, metastatic Breast Cancer (BC) is still incurable. Targeting the cell cycle machinery has emerged as an attractive strategy to tackle cancer progression, sho...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2017-04, Vol.112, p.208-214
Main Authors: Corona, Silvia Paola, Ravelli, Andrea, Cretella, Daniele, Cappelletti, Maria Rosa, Zanotti, Laura, Dester, Martina, Gobbi, Angela, Petronini, Pier Giorgio, Generali, Daniele
Format: Article
Language:English
Subjects:
Abemaciclib
Advanced breast cancer
Breast cancer
Breast Neoplasms - drug therapy
Cyclin-Dependent Kinase 4 - antagonists & inhibitors
Cyclin-Dependent Kinase 6 - antagonists & inhibitors
Cyclin-dependent kinases (CDK)
Estradiol - analogs & derivatives
Estradiol - therapeutic use
Hematology, Oncology and Palliative Medicine
HER2 positive BC
Humans
Molecular Targeted Therapy - methods
Nitriles - therapeutic use
Palbociclib
Protein Kinase Inhibitors - therapeutic use
Receptor, ErbB-2 - biosynthesis
Ribociclib
Triazoles - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Notwithstanding the continuous progress made in cancer treatment in the last 20 years, and the availability of new targeted therapies, metastatic Breast Cancer (BC) is still incurable. Targeting the cell cycle machinery has emerged as an attractive strategy to tackle cancer progression, showing very promising results in the preclinical and clinical settings. The first selective inhibitors of CDK4/6 received breakthrough status and FDA approval in combination with letrozole (February 2015) and fulvestrant (February 2016) as first-line therapy in ER-positive advanced and metastatic BC. Considering the success of this family of compounds in hormone-positive BC, new possible applications are being investigated in other molecular subtypes. This review summarizes the latest findings on the use of CDK4/6 inhibitors in HER2 positive BC.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2017.02.022